What Asthma Trials Actually Look Like in the UK
Clinical trials are not confined to sterile labs with flickering fluorescent lights. In the UK, much of this research happens in NHS hospitals, often in the same respiratory departments where patients already attend their regular appointments. Asthma clinical trials can range from testing a new biologic injection to evaluating whether a different way of using an existing inhaler leads to better outcomes.
The UK has a strong track record in respiratory research. Institutions like the Royal Brompton Hospital in London, Wythenshawe Hospital in Manchester, and the Oxford University Hospitals NHS Foundation Trust have been at the centre of major asthma studies. One recent example is the phase two ABRA clinical trial, which investigated whether benralizumab—a drug already used for severe asthma—could be given at the point of an asthma attack to reduce the need for repeat steroid courses and hospitalisation. The results suggested that targeting specific inflammatory pathways during an exacerbation could change how emergency care is delivered.
Another significant development came in December 2025, when the MHRA authorised depemokimab (brand name Exdensur) for adults and adolescents with type 2 inflammation-driven asthma. This biologic stands out because it requires only twice-yearly dosing, making it the first ultra-long-acting option of its kind. The approval was based on the SWIFT and ANCHOR phase III trials, which showed sustained reductions in exacerbations and fewer hospitalisations.
For patients with severe asthma, biologic treatment trials represent a particularly important area of inquiry. The UK Severe Asthma Registry has been used to analyse how these therapies perform in real-world populations—people who might not have met the strict criteria of earlier randomised controlled trials. Research published in early 2026 in ERJ Open Research examined the effectiveness of biologics in patients who would have been ineligible for the original phase III studies, providing valuable insight into how these treatments work beyond the controlled trial setting.
Who Can Join and What to Expect
Every trial has its own eligibility criteria, but some patterns are common. Researchers typically look for participants whose asthma falls into a specific category—perhaps eosinophilic asthma, allergic asthma, or asthma that has not responded well to standard inhaled corticosteroids. Asthma clinical trial eligibility often depends on factors like age, lung function measurements, exacerbation history, and blood eosinophil levels.
Before signing up, you will go through a screening process. This usually involves a conversation with the research team, a review of your medical history, and some baseline tests. If you qualify, you will be given a detailed participant information sheet explaining what the trial involves, how long it runs, and what the potential risks and benefits are. Informed consent is a legal requirement, and you can withdraw at any time without it affecting your standard NHS care.
Claire Newman, a 48-year-old from Bexley, described what it was like to receive tezepelumab through a trial at the Royal Brompton. "My asthma really limits what I can do," she said. "Simple things like just moving around the flat is a real struggle. Housework, which I used to be able to do without a problem, is now just off limits because it can trigger asthma attacks." After trying other biologics without success, she found that tezepelumab offered meaningful improvement. Her experience illustrates why many patients choose to participate: sometimes the treatments available through standard care are simply not enough.
Comparing Research Pathways
The table below provides an overview of the different types of asthma studies you might encounter in the UK, along with what they typically involve.
| Study Type | Example | Typical Duration | Who It Suits | Key Considerations |
|---|
| Biologic treatment trial | Depemokimab (SWIFT/ANCHOR) | 12–24 months | Adults/adolescents with eosinophilic asthma inadequately controlled on ICS | Regular injections; frequent monitoring visits |
| Repurposed drug trial | Benralizumab for acute attacks (ABRA) | Single-attack intervention | Patients presenting with eosinophilic exacerbations | One-time treatment at emergency setting |
| Self-management trial | IMP2ART in primary care | 12–18 months | Adults with asthma in GP practices | Focuses on behaviour change, not new medication |
| Observational study | Biologic experience survey (Royal Devon) | Retrospective | People already on biologics | No medication changes; questionnaires only |
| Paediatric trial | HiFlo for acute severe asthma | During hospital admission | Children aged 2–11 with acute severe asthma | Involves oxygen delivery method comparison |
Where to Find Trials Near You
The most straightforward starting point is the Be Part of Research website, which aggregates clinical trials from multiple UK registries. You can search by condition, location, and other filters to find asthma clinical trials near you. The site also allows you to contact research teams directly if a study looks relevant.
Asthma + Lung UK, the charity formed by the merger of Asthma UK and the British Lung Foundation, maintains a research section that highlights ongoing studies and explains how patients can get involved. Their resources are written in plain English and are designed for people who have never participated in research before.
For those who prefer a more personal route, your GP or respiratory consultant can be an excellent source of information. Many NHS trusts have dedicated research and development departments, and hospital staff are often aware of trials recruiting locally. In cities like London, Manchester, Birmingham, and Glasgow, dedicated severe asthma centres routinely participate in multi-centre studies.
The Manchester Asthma and Allergy Study (MAAS) is an example of a long-running research programme that has been tracking participants from birth into adulthood. Its latest follow-up phase, running until 2028, is examining how early-life factors influence respiratory outcomes decades later. Studies like this contribute to the broader understanding of asthma as a lifelong condition, not just a series of isolated episodes.
What Happens to Your Data and Safety
All clinical trials in the UK must be approved by a research ethics committee and, where applicable, by the MHRA. The Health Research Authority (HRA) oversees the governance framework. Your personal data is handled in line with GDPR and NHS data protection standards. Trial results are typically published in peer-reviewed journals, but individual participants are never identifiable from published data.
The IMP2ART trial, which is testing a strategy to implement improved asthma self-management in primary care across the UK, published its internal pilot findings in early 2026. These kinds of implementation studies are particularly relevant because they examine how to make proven interventions work in everyday GP surgeries, not just in specialist centres.
It is worth keeping in mind that not every trial delivers a breakthrough. Some interventions turn out to be no better than existing treatments. But even negative results contribute to medical knowledge by ruling out dead ends and redirecting resources toward more promising avenues. The UK research community has been transparent about this, and the ISRCTN registry ensures that trial protocols and results are publicly accessible.
If you are considering joining a study, you might want to ask the research team a few practical questions: How many visits are required? Will travel expenses be covered? What happens if you experience a side effect? Will your GP be informed? Most UK trials reimburse reasonable travel costs, and some offer compensation for time spent attending visits, though the specifics vary by study.
The landscape of asthma research in the UK is shifting. With biologics becoming more targeted, self-management tools being refined in primary care, and repurposed drugs offering new approaches to acute attacks, the opportunities to contribute to—and benefit from—clinical research have never been broader. The Be Part of Research website is a sensible place to begin looking, as is a conversation with your respiratory team at your next appointment.
研究の知恵